Biochanin A is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Biochanin A. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Biochanin A. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Biochanin A. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Biochanin A. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Biochanin A. |
| Lenalidomide | Biochanin A may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Biochanin A is combined with Ospemifene. |
| Ropinirole | Biochanin A may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Biochanin A may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Biochanin A may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Biochanin A may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Biochanin A may increase the thrombogenic activities of Omalizumab. |
| Adalimumab | Biochanin A may increase the thrombogenic activities of Adalimumab. |
| Gemtuzumab ozogamicin | Biochanin A may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Biochanin A may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Infliximab | Biochanin A may increase the thrombogenic activities of Infliximab. |
| Trastuzumab | Biochanin A may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Biochanin A may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Biochanin A may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Biochanin A may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Biochanin A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Biochanin A may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Biochanin A may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Biochanin A may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Biochanin A may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Biochanin A may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Biochanin A may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Biochanin A may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Biochanin A may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Biochanin A may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Biochanin A may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Biochanin A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Biochanin A may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Biochanin A may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Biochanin A may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Biochanin A may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Biochanin A may increase the thrombogenic activities of Pexelizumab. |
| Afelimomab | Biochanin A may increase the thrombogenic activities of Afelimomab. |
| Epratuzumab | Biochanin A may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Biochanin A may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Biochanin A may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Biochanin A may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Biochanin A may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Biochanin A may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Biochanin A may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Biochanin A may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Biochanin A may increase the thrombogenic activities of Bavituximab. |
| CR002 | Biochanin A may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Biochanin A may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Biochanin A may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Biochanin A may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Biochanin A may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Biochanin A may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Biochanin A may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Biochanin A may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Biochanin A may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Biochanin A may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Biochanin A may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Biochanin A may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Biochanin A may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Biochanin A may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Biochanin A may increase the thrombogenic activities of Ustekinumab. |
| Trastuzumab emtansine | Biochanin A may increase the thrombogenic activities of Trastuzumab emtansine. |
| PRO-542 | Biochanin A may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Biochanin A may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Biochanin A may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Biochanin A may increase the thrombogenic activities of RI 624. |
| Stamulumab | Biochanin A may increase the thrombogenic activities of MYO-029. |
| CT-011 | Biochanin A may increase the thrombogenic activities of CT-011. |
| Leronlimab | Biochanin A may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Biochanin A may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Biochanin A may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Biochanin A may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Biochanin A may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Biochanin A may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Biochanin A may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Biochanin A may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Biochanin A may increase the thrombogenic activities of Lumiliximab. |
| Canakinumab | Biochanin A may increase the thrombogenic activities of Canakinumab. |
| Ipilimumab | Biochanin A may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Biochanin A may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Biochanin A may increase the thrombogenic activities of Clenoliximab. |
| Tocilizumab | Biochanin A may increase the thrombogenic activities of Tocilizumab. |
| BIIB015 | Biochanin A may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Biochanin A may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Biochanin A may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Biochanin A may increase the thrombogenic activities of Elotuzumab. |
| AVE9633 | Biochanin A may increase the thrombogenic activities of AVE9633. |
| Carotuximab | Biochanin A may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Biochanin A may increase the thrombogenic activities of XmAb 2513. |
| Coltuximab ravtansine | Biochanin A may increase the thrombogenic activities of Coltuximab ravtansine. |
| Lucatumumab | Biochanin A may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Biochanin A may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Biochanin A may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Biochanin A may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Biochanin A may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Biochanin A may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Biochanin A may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Biochanin A may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Biochanin A may increase the thrombogenic activities of Reslizumab. |